CureVac Gains Favorable Patent Decision Against BioNTech

CureVac has announced a favorable decision from the European Patent Office (EPO) in its ongoing patent litigation against BioNTech. The EPO upheld the validity of CureVac's patent EP 4 023 755 B1, although with amendments to certain claims. This follows a March ruling where the validity of another CureVac patent, EP 3 708 668 B1, was also confirmed in amended form.

The litigation involves six intellectual property rights and is set for a hearing on July 1, 2025, at the Regional Court of Düsseldorf, Germany, to determine possible patent infringement. This legal dispute is crucial as CureVac aims to protect its split poly-A tail technology, which enhances mRNA expression efficacy, an area in which both CureVac and BioNTech are key players.